Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 73 | 75 | +2 |
| Shares | 20.0M | 20.5M | +508.1K (+2.5%) |
| Value | $291.7M | $350.8M | +$59.1M (+20.2%) |
New holders (9)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Oconnor LLC | 61,000 | $1.04M | 0.01% |
| XTX Topco Ltd | 17,865 | $306.0K | 0.08% |
| Susquehanna International Group, LLP | 14,257 | $244.0K | 0.00% |
| Sargent Investment Group, LLC | 10,858 | $187.0K | 0.06% |
| Public Employees Retirement System of Ohio | 5,500 | $94.0K | 0.00% |
| Signaturefd, LLC | 224 | $4.00K | 0.00% |
| US Bancorp | 136 | $2.00K | 0.00% |
| Massmutual Trust Co FSB | 23 | $0 | 0.00% |
| Allworth Financial LP | 12 | $0 | 0.00% |
Sold out (7)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Alyeska Investment Group, L.P. | 75,000 | $1.09M |
| Islet Management, LP | 63,310 | $924.0K |
| SG Americas Securities, LLC | 50,512 | $737.0K |
| Citadel Advisors LLC | 20,873 | $305.0K |
| Cubist Systematic Strategies, LLC | 13,669 | $200.0K |
| Prentice Wealth Management LLC | 250 | $4.00K |
| Spire Wealth Management | 50 | $1.00K |